| 1 |
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
Richard J. Mills et al. · Cell
Open access |
18 Mar 2021 |
240 |
| 2 |
RVX-208
Dana Bailey, Ravi Jahagirdar, ALLAN S. GORDON et al. · Journal of the American College of Cardiology
Open access |
Jun 2010 |
233 |
| 3 |
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
Kevin G. McLure, Emily M. Gesner, Laura M. Tsujikawa et al. · PLoS ONE
Open access |
31 Dec 2013 |
201 |
| 4 |
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease
Stephen James Nicholls, ALLAN S. GORDON, Jan Erik Johansson et al. · Journal of the American College of Cardiology
Open access |
24 Jan 2011 |
174 |
| 5 |
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes
Kausik Kumar Ray, Stephen James Nicholls, Kevin A. Buhr et al. · JAMA
Open access |
27 Mar 2020 |
172 |
| 6 |
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension
Diederik E. van der Feen, Kondababu Kurakula, Ève Tremblay et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
May 2019 |
166 |
| 7 |
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
Ravi Jahagirdar, Haiyan Zhang, Salman Azhar et al. · Atherosclerosis
|
28 Jun 2014 |
134 |
| 8 |
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
Laura M. Tsujikawa, Li Fu, Shovon Das et al. · Clinical Epigenetics
Open access |
12 Jul 2019 |
131 |
| 9 |
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham, Sylwia Wasiak, Laura M. Tsujikawa et al. · Atherosclerosis
Open access |
22 Jan 2016 |
115 |
| 10 |
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Ewelina Kulikowski, Brooke D. Rakai, Norman C.W. Wong · Medicinal Research Reviews
Open access |
14 Sep 2020 |
107 |
| 11 |
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies
Stephen James Nicholls, ALLAN S. GORDON, Jan Johannson et al. · Cardiovascular Drugs and Therapy
|
16 Feb 2012 |
92 |
| 12 |
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
the BETonMACE Investigators, Stephen James Nicholls, Gregory G. Schwartz et al. · Cardiovascular Diabetology
Open access |
7 Jan 2021 |
86 |
| 13 |
Apabetalone downregulates factors and pathways associated with vascular calcification
Dean Gilham, Laura M. Tsujikawa, Christopher D. Sarsons et al. · Atherosclerosis
Open access |
14 Nov 2018 |
67 |
| 14 |
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome
Kamyar Kalantar‐Zadeh, Gregory G. Schwartz, Stephen James Nicholls et al. · Clinical Journal of the American Society of Nephrology
Open access |
27 Apr 2021 |
59 |
| 15 |
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
Ravi Jahagirdar, Sarah Attwell, Suzana Marušić et al. · Molecular Pharmacology
Open access |
4 Oct 2017 |
59 |
| 16 |
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Kausik Kumar Ray, Stephen James Nicholls, Henry Ginsberg et al. · American Heart Journal
Open access |
9 Aug 2019 |
57 |
| 17 |
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
Sylwia Wasiak, Dean Gilham, Laura M. Tsujikawa et al. · Journal of Cardiovascular Translational Research
Open access |
31 May 2017 |
50 |
| 18 |
BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial
Steeve Provencher, François Potus, Pascale Blais-Lecours et al. · American Journal of Respiratory and Critical Care Medicine
|
15 Mar 2022 |
48 |
| 19 |
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
Ewelina Kulikowski, Christopher Halliday, Jan Johansson et al. · Kidney & Blood Pressure Research
Open access |
2018 |
48 |
| 20 |
The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial
Daisuke Shishikura, Yu Kataoka, Satoshi Honda et al. · American Journal of Cardiovascular Drugs
|
28 Aug 2018 |
43 |
| 21 |
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
Sylwia Wasiak, Kim E. Dzobo, Brooke D. Rakai et al. · Clinical Epigenetics
Open access |
11 Nov 2020 |
42 |
| 22 |
Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease
Mathias Loberg Haarhaus, Kausik Kumar Ray, Stephen James Nicholls et al. · Atherosclerosis
Open access |
17 Sep 2019 |
42 |
| 23 |
Benefit of Apabetalone on Plasma Proteins in Renal Disease
Sylwia Wasiak, Laura M. Tsujikawa, Christopher Halliday et al. · Kidney International Reports
Open access |
8 Dec 2017 |
42 |
| 24 |
A Machine Learning Approach for Collusion Detection in Electricity Markets Based on Nash Equilibrium Theory
Peyman Razmi, Majid Oloomi Buygi, Mohammad Esmalifalak · Journal of Modern Power Systems and Clean Energy
Open access |
2021 |
38 |
| 25 |
Perspective on the Discovery and Scientific Impact of p38 MAP Kinase
Peter R. Young · SLAS DISCOVERY
Open access |
29 Jul 2013 |
36 |
| 26 |
Validation of an Overnight Wireless High-Resolution Oximeter plus Cloud-Based Algorithm for the Diagnosis of Obstructive Sleep Apnea
George do Lago Pinheiro, Andrea Fonseca Cruz, Diego Munduruca Domingues et al. · Clinics
Open access |
2020 |
34 |
| 27 |
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
Dean Gilham, Audrey L. Smith, Li Fu et al. · Biomedicines
Open access |
18 Apr 2021 |
32 |
| 28 |
Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
Mathias Loberg Haarhaus, Dean Gilham, Ewelina Kulikowski et al. · Current Opinion in Nephrology & Hypertension
Open access |
12 Nov 2019 |
31 |
| 29 |
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
Gregory G. Schwartz, Stephen James Nicholls, Peter Paul Toth et al. · Cardiovascular Diabetology
Open access |
22 Jun 2021 |
27 |
| 30 |
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
Jeffrey L. Cummings, Gregory G. Schwartz, Stephen James Nicholls et al. · Journal of Alzheimer s Disease
Open access |
24 Aug 2021 |
25 |
| 31 |
Metabolic Control by S6 Kinases Depends on Dietary Lipids
Tamara R. Castañeda, William A. Abplanalp, Sung Hee Um et al. · PLoS ONE
Open access |
7 Mar 2012 |
24 |
| 32 |
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells
Sylwia Wasiak, Laura M. Tsujikawa, Emily Daze et al. · Atherosclerosis
|
23 Nov 2022 |
23 |
| 33 |
In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)
Yuri L. Khmelnitsky, Vadim V. Mozhaev, Ian C. Cotterill et al. · European Journal of Medicinal Chemistry
|
16 Apr 2013 |
19 |
| 34 |
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
Peter Paul Toth, Gregory G. Schwartz, Stephen James Nicholls et al. · American Journal of Preventive Cardiology
Open access |
8 Aug 2022 |
16 |
| 35 |
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Li Fu, Sylwia Wasiak, Laura M. Tsujikawa et al. · Pharmacology Research & Perspectives
Open access |
13 Apr 2022 |
15 |
| 36 |
Stilbene analogs as inducers of apolipoprotein-I transcription
Henrik Claus Hansen, Fabrizio S. Chiacchia, Reena G. Patel et al. · European Journal of Medicinal Chemistry
|
15 Jan 2010 |
15 |
| 37 |
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
Sylwia Wasiak, Dean Gilham, Emily Daze et al. · Cardiovascular Therapeutics
Open access |
Aug 2020 |
14 |
| 38 |
Synthesis of 2-aryl-4H-pyrano[2,3-b]pyridin-4-ones by a one-pot deprotection–cyclization reaction
Vladimir Khlebnikov, Kalpesh Patel, Xiaojian Zhou et al. · Tetrahedron
|
22 Jun 2009 |
14 |
| 39 |
Dose Density by Any Other Name
William M. Hryniuk, Joseph Ragaz, William P. Peters · Journal of Clinical Oncology
|
14 Feb 2004 |
13 |
| 40 |
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
Dean Gilham, Sylwia Wasiak, Brooke D. Rakai et al. · Biomedicines
Open access |
8 Jun 2023 |
12 |
| 41 |
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators
Laura M. Tsujikawa, Olesya A. Kharenko, Stephanie C. Stotz et al. · Biomedicine & Pharmacotherapy
Open access |
6 Jun 2022 |
11 |
| 42 |
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
Li Fu, Dean Gilham, Stephanie C. Stotz et al. · International Immunopharmacology
Open access |
23 Feb 2023 |
6 |
| 43 |
Insulin mimetic effect of D‐allulose on apolipoprotein A‐I gene
Michael J. Haas, Shrina Parekh, Poonam Kalidas et al. · Journal of Food Biochemistry
Open access |
5 Jan 2022 |
6 |
| 44 |
Therapies to Increase ApoA-I and HDL-Cholesterol Levels
William M. Brown, Fabrizio S. Chiacchia · Drug Target Insights
Open access |
2008 |
5 |
| 45 |
The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening
Rajnish Vasant Nagarkar, Gopichand Mamillapalli, Suparna Kanti Pal et al. · International Journal of Women s Health
Open access |
2024 |
4 |
| 46 |
Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation
Jamshed J Dalal, Wael A. Almahmeed, Rungroj Krittayaphong et al. · Journal of Asian Pacific Society of Cardiology
Open access |
20 Jan 2023 |
4 |
| 47 |
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
Christopher D. Sarsons, Dean Gilham, Laura M. Tsujikawa et al. · Biomedicines
Open access |
30 Sep 2023 |
3 |
| 48 |
Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical)
Richard J. Mills et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
24 Aug 2020 |
3 |
| 49 |
Click, click, who's there?
Marc Boroditsky · Network Security
|
Nov 2010 |
3 |
| 50 |
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activationin vitroand in a mouse model of systemic inflammation
Sylwia Wasiak, Li Fu, Emily Daze et al. · Translational Neuroscience
Open access |
2023 |
2 |